Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 11;25(4):617–627. doi: 10.1093/neuonc/noac236

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 2. — Schematic representation of the most important cellular immunotherapeutic strategies for medulloblastoma. B7-H3, B7 homolog 3; CAR, chimeric antigen receptor; CD1d, cluster of differentiation 1; DC, dendritic cell; EGFR, epidermal growth factor receptor; EPHA2, ephrin type-A receptor 2; HER2, human epidermal growth factor receptor 2; IL13-Rα2, interleukin-13 receptor subunit alpha-2; MHC-I, major histocompatibility complex type I; NK, natural killer; NKCR, NK cell receptor; NKG2DL, ligands of NKG2D; PRAME, antigen preferentially expressed in melanoma; TCR, T cell receptor, ttRNA; total tumor RNA. Figure was generated based on the available literature.^{22,26,47–49,52–63}.